Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment.
washington; swedish; swedish cancer
There is a lack of consensus on therapy sequencing in previously treated multiple myeloma, particularly after anti-B-cell maturation antigen (BCMA) therapy. Earlier reports on selinexor (X) regimens demonstrated considerable efficacy in early treatment, and after anti-BCMA-targeted chimeric antigen receptor-T cell therapy. Here, we present data from 11 heavily pretreated patients who predominantly received BCMA-antibody-drug conjugate therapy. We observe that X-containing regimens are potent and achieve durable responses with numerically higher overall response and clinical benefit rates, as well as median progression free survival compared to patients' prior anti-BCMA therapies, despite being used later in the treatment course. In an area of evolving unmet need, these data reaffirm the efficacy of X-based regimens following broader anti-BCMA therapy.
Baljevic, Muhamed; Gasparetto, Cristina; Schiller, Gary J; Tuchman, Sascha A; Callander, Natalie S; Lentzsch, Suzanne; Monge, Jorge; Kotb, Rami; Bahlis, Nizar J; White, Darrell; Chen, Christine I; Sutherland, Heather J; Madan, Sumit; LeBlanc, Richard; Sebag, Michael; Venner, Christopher P; Bensinger, William; Biran, Noa; DeCastro, Andrew; Van Domelen, Dane R; Zhang, Chris; Shah, Jatin J; Shacham, Sharon; Kauffman, Michael G; Bentur, Ohad S; and Lipe, Brea, "Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment." (2022). Articles, Abstracts, and Reports. 6795.